

# Non-Compartmental PK Modelling

“model independent”

Distributed models

Transit/Residence distributions

Michael Weiss

michael.weiss@medizin.uni-halle.de

Martin Luther University

Halle-Wittenberg



## Basic Equation

$$\frac{dA_e(t)}{dt} = CL C(t) \quad (1)$$

**Rate of drug elimination = Clearance x Plasma concentration**

(→ “model independent “ or noncompartmental analysis)

$$\int_0^{\infty} \frac{dA_e(t)}{dt} = A_e(\infty) \equiv D_{iv} = CL \int_0^{\infty} C(t) dt$$
$$D_{iv} = CL AUC$$

Well-mixed plasma compartment !


Note:  $A_e(\infty) \equiv D_{iv}$  (nothing remains in the body)

# Estimation of Clearance (single dose)

$$CL = \frac{D_{iv}}{AUC}$$

Intravenous dose

Area Under the Curve



Single dose

$$AUC = \int_0^{\infty} C(t) dt$$


! (indicated by a red arrow pointing to the infinity symbol)

# Estimation of Clearance (infusion)

Steady state after continuous  
i.v. infusion

$$\text{Elimination rate} = CL C_{ss}$$


$$\text{Dose rate} = DR$$





$$CL = \frac{DR}{C_{ss}}$$

# Estimation of Bioavailability

$A_e$    $\Rightarrow$  Amount that reaches the systemic circulation


$$A_e \text{  } = CL \int_0^{\infty} C(t) dt \quad (\text{cf. Eq. 1})$$

$$F = \frac{A_{e,or} \text{  }}{A_{e,iv} \text{  }} = \frac{CL \int_0^{\infty} C_{or}(t) dt}{CL \int_0^{\infty} C_{iv}(t) dt} = \frac{AUC_{or}}{AUC_{iv}} \quad (13)$$

Assumption: CL unchanged !
-------------------------------

$$\text{if } D_{or} \neq D_{iv} : F = \frac{D_{iv} AUC_{or}}{D_{or} AUC_{iv}}$$

# Determinants of Clearance



$$CL_{organ} = Q_{organ} E_{organ} \quad (4)$$


$$CL = CL_H + CL_R \quad (+CL_{other})$$

*hepatic*      *renal*

$$CL = \sum_{i=1}^N Q_i E_i$$

# Renal Clearance

$$CL_R = \frac{A_{eR, t_1 \rightarrow t_2}}{\int_{t_1}^{t_2} C(t) dt} \quad (5)$$



$$= \frac{\text{amount excreted}_{t_1 \rightarrow t_2}}{AUC_{t_1 \rightarrow t_2}}$$

$$CL_H = CL - CL_R$$

## Relative Bioavailability

$$\frac{F_{Treat}}{F_{Con}} = \frac{AUC_{or,Treat}}{AUC_{iv,Treat}} \frac{AUC_{iv,Con}}{AUC_{or,Con}}$$



# Residence Time Distribution

If an amount of drug molecules (dose  $D$ ) is instantaneously injected intravenously, each molecule will spend a random time  $T$  in the body until it is eliminated (the disposition residence time of that molecule).

Residence time distribution,  $F(t)$ , is defined by the fraction of molecules which have a residence time less than  $t$ :

$$F(t) = \Pr [T < t] = \frac{A_e(t)}{D}$$

$A_e(t)$  is the cumulative amount of drug eliminated up to time  $t$ .


$$F(0) = 0 \text{ and } F(\infty) = 1$$

$$\frac{dA_e(t)}{dt} = CL C(t)$$

**Density function**


$$f(t) = \frac{C(t)}{\int_0^{\infty} C(t) dt} = \frac{C(t)}{AUC}$$

# Mean Residence Time

$$MRT = E[T] = \int_0^{\infty} t f(t) dt = \int_0^{\infty} \bar{F}(t) dt = \int_0^{\infty} [1 - F(t)] dt$$


$$MRT = \frac{\int_0^{\infty} t C(t) dt}{AUC}$$

$$MRT = \frac{\int_0^{\infty} [A_{e,R}(\infty) - A_{e,R}(t)] dt}{A_{e,R}(\infty)}$$

$$-\frac{dA_e(t)}{dt} = CLC(t)$$


$\bar{F}(t) = P[T > t]$       Probability that residence time  $T$  of a molecule exceeds  $t$ .

**Continuous infusion:** Mass  $dA$  which entered the body in the time interval  $[t-dt, t]$  which remains in the body at time  $t$  is given by:

$$DR \bar{F}(t) dt$$

$$\rightarrow A(t) = DR \int_0^t \bar{F}(t) dt \quad \rightarrow \quad A_{ss} = A(\infty) = DR \int_0^{\infty} \bar{F}(t) dt$$

$$\rightarrow A_{ss} = DR MDRT$$

$$V_{ss} = \frac{A_{ss}}{C_{ss}} = \frac{DR MDRT}{C_{ss}} = MDRT CL$$

# 1. Disposition Curves (Bolus Injection)

Clearance

$CL$

Volume of distribution at steady state

$V_{ss}$



**Mean Disposition Residence Time**

$MDRT$

$$MDRT = \frac{V_{ss}}{CL}$$

(14)


# Mean Disposition Residence Time




$$t_{90\%} \leq 3.7 MDRT \quad (15)$$

$$t_{90\%} \approx 4 t_{1/2}$$

# Multiple Dosing




# Therapeutic Drug Monitoring (TDM)



$$AUC_{ss} = AUC$$

$$\bar{C}_{ss} = \frac{DR}{CL} = \frac{FD_m}{CL\tau}$$



$$\frac{\text{amount in body at steady state}}{\text{maintenance dose}} = \frac{MDRT}{\tau}$$



# Basic Pharmacokinetic Parameters

- *CL* determines maintenance dose  $D_m$
- *V* determines loading dose  $D_L$
- *MDRT* determines time to steady state  $t_{90\%}$   
and dosing interval  $\tau$


## Parametric Curve Model

$$C_{iv}(t) = \sum_{i=1}^n B_i e^{-\lambda_i t} \quad \text{fit to data, estimate } B_i \text{ and } \lambda_i \text{ (} i=1..n \text{)}$$

$$CL = \frac{D_{iv}}{\sum_{i=1}^n \frac{B_i}{\lambda_i}} \quad \int_0^{\infty} C(t) dt = AUC = \sum_{i=1}^n \frac{B_i}{\lambda_i}$$

$$MDRT = \frac{\int_0^{\infty} t C_{iv}(t) dt}{\int_0^{\infty} C_{iv}(t) dt} = \frac{AUMC_{iv}}{AUC_{iv}} = \frac{\sum_{i=1}^n \frac{B_i}{\lambda_i^2}}{\sum_{i=1}^n \frac{B_i}{\lambda_i}} \quad V_{SS} = CL MDRT$$

# Mean Residence Time after Oral and Intravenous Administration



$$MBRT = MDT + MAT + MDRT$$

## Mean Disposition Residence Time

*MDRT*

$$MDRT = \frac{\int_0^{\infty} t C_{iv}(t) dt}{\int_0^{\infty} C_{iv}(t) dt} = \frac{AUMC_{iv}}{AUC_{iv}}$$

## Mean Body Residence Time

*MBRT*

$$MBRT = \frac{\int_0^{\infty} t C_{or}(t) dt}{\int_0^{\infty} C_{or}(t) dt} = \frac{AUMC_{or}}{AUC_{or}}$$

# Oral Administration

Mean Input Time



$$MIT = MDT + MAT$$

Dissolution

$$MDT = MBRT_{Tablet} - MBRT_{Solution}$$

Absorption

$$MAT = MBRT_{Solution} - MDRT$$




# $C(t)$ after extravascular (oral) administration

$$\int_0^{\infty} C(t) dt = AUC \quad \text{and} \quad \int_0^{\infty} tC(t) dt = AUMC$$


by numerical integration

**Trapezoidal rule**



## Trapezoidal rule


$$\begin{aligned}
 AUC &= \sum_{i=1}^{N-1} \frac{1}{2} (C_i + C_{i+1}) (t_{i+1} - t_i) + \frac{C_N}{\lambda_z} \\
 &= AUC_{0,t_N} + AUC_{t_N,\infty}
 \end{aligned}$$




$$\begin{aligned}
 AUMC &= \sum_{i=1}^{N-1} \frac{1}{2} (t_i C_i + t_{i+1} C_{i+1}) (t_{i+1} - t_i) + C_N \left( \frac{t_N}{\lambda_z} + \frac{1}{\lambda_z^2} \right) \\
 &= AUMC_{0,t_N} + AUMC_{t_N,\infty}
 \end{aligned}$$

# How to describe mixing/distribution kinetics ?


## Steady-state $\rightarrow$ transient state



Reactor:  
Turbulent mixing




Circulation without dispersion:  
no mixing



Transit time dispersion  
in microcirculatory network:  
mixing



## Residence time sytem




**Mean transit time**

**Transit time dispersion**



## Transit time sytem



**Extent of distribution**

**Rate of distribution**

# Relative Dispersion of Disposition Residence Time Distribution

Normalized (dimensionless) variance

$$RD_D^2 = \frac{VDRT}{MDRT^2}$$

$$C_{iv}(t) = \sum_{i=1}^n B_i e^{-\lambda_i t}$$

$$m_j = \int_0^{\infty} t^j C(t) dt = j! \sum_{i=1}^n \frac{B_i}{\lambda_i^{j+1}}$$

$$VDRT = \frac{m_2}{m_0} - \left( \frac{m_1}{m_0} \right)^2$$

$$MDRT = \frac{m_1}{m_0}$$



# Rate of Distribution: Mixing Clearance

Closed (noneliminating) system ( $CL = 0$ )



$$V_0 \frac{dC(t)}{dt} = -CL_M [C(t) - C(\infty)]$$

$$\frac{AUC_M}{AUC} = \frac{1}{2} (1 - RD_D^2)$$


$$CL_M = \frac{D_{iv}}{AUC_M} = \frac{2CL}{1 - RD_D^2}$$



# $AUC_M$ : Circulatory Transit Time



Closed  
(noneliminating)  
system ( $CL = 0$ )




$$AUC_M = \frac{D_{iv}}{Q} \frac{1}{2} (RD_c^2 - 1)$$


$$RD_D^2 - 1 = \frac{CL}{Q} (RD_c^2 - 1)$$

# From Flow-to Diffusion-Limited Distribution Kinetics

## A Continuous Transition





# Distribution Kinetics of Alfentanil




$$C_{iv}(t) = \sum_{i=1}^4 B_i e^{-\lambda_i t} \quad m_j = j! \sum_{i=1}^4 \frac{B_i}{\lambda_i^{j+1}}$$


$Q$  (l/min)

# Thiopental: heterogeneity of residence time distribution increases with obesity





# Minimal Circulatory PK Model



Heterogeneous subsystems  
Transit time distributions



Less than 0.1% of PK models used in literature are circulatory models

## Why are they relevant?

### 1) Description of initial mixing kinetics (2 min after bolus injection)

*Front-end kinetics of short acting iv anesthetics*


### 2) First-principles modeling of distribution kinetics

*Role of cardiac output, convective dispersion and intratissue diffusion  
(ICG, inulin, antipyrine, thiopental, rocuronium)*

*Modeling of slow tissue binding (digoxin)*

*Use of the multiple indicator approach in parameter estimation*

# Circulatory minimal model



# Recirculatory PK Model

$$\hat{f}_{circ}(s) = \frac{\hat{f}_p(s)}{1 - (1 - E)\hat{f}_s(s)\hat{f}_p(s)}$$

$$E = \frac{CL}{Q} \quad \text{Extraction (probability of elimination in one passage through systemic circulation)}$$



## Numerical inverse Laplace Transformation

Schalla & Weiss, Eur J Pharm Sci, 1999


$$C(t) = L^{-1} \left\{ \frac{D}{Q} \hat{f}_{circ}(s) \right\}$$

# Hemodynamic Influences on Sorbitol Kinetics in Humans

## Inverse Gaussian Transit Time Density






# Physiological (recirculatory)




vs.

# Compartmental (biexponential)




Time (min)

# Arterial vs. peripheral venous sampling




# First-principles modeling of distribution kinetics



**Advective transport**

Advective dispersion → Vascular mixing




**Permeation (Capillary uptake)**

**Diffusion (Extravascular)**


**Tissue Binding**

# Drug+vascular marker (ICG)

1. Simultaneous injection, ICG+drug
2. Fit of ICG data (IG model)
3. Fixing of ICG parameters in drug model
4. Fit of drug data









# Systemic circulation: Advection-diffusion model

Stochastic model of transit time distribution

Microcirculatory network




Microscopic volume element



# Extravascular Diffusion Kinetics


Rocuronium (+ICG as vascular marker)



$$v = \frac{V_T}{V_B}$$



$$\tau_d = \frac{L^2}{D_{eff}}$$

$$\hat{f}_s(s) = \hat{f}_{IG} \left( s + \frac{v_s}{\tau_d} \sqrt{\tau_d s} \tanh \sqrt{\tau_d s} \right)$$



# Vascular Mixing Kinetics


## Vascular Marker (ICG) in Patient



		Population Mean	Interpatient CV(%)
Cardiac output	$Q$ (L/min)	3.52	20
TT dispersion	Pulmonary circulation	$RD_{B,p}^2$	0.09
	Systemic circulation	$RD_{B,s}^2$	0.37

Weiss et al.,  
J Pharmacokin  
Pharmacodyn, 2011


# Rocuronium Kinetics in Patients




Individual estimates of ICG parameters were used as fixed parameters in fitting rocuronium data.

Distribution kinetics of rocuronium

		Population Mean (%RSE)	Interpatient %CV (%RSE)
Interstitial diffusion, time constant	$\tau_d$ (min)	89 (37)	50(62)
	$V_{T,p}$ (L)	2.66(97)	115 (61)
Interstitial volumes	$V_{T,s}$ (L)	14.2 (30)	29 (96)



**Central blood volume increases linearly with cardiac output ( $P < 0.01$ )**



**Systemic transit time heterogeneity of ICG decreases linearly with cardiac output ( $P < 0.005$ )**

# Conclusions

Minimal PBPK models are relevant for explaining

- Initial intravascular mixing  
(blood volumes, TT dispersion, role of the lungs)
- Tissue distribution kinetics (permeation,diffusion,binding)
- Effect of obesity (highly lipid-soluble drugs)
- Effect of cardiac output and hemorrhagic shock
- Hemodynamic drug interactions
- Hepatic function in vivo (ICG)

Model selection and experimental design are strongly interrelated:  
Frequent early blood sampling and multiple indicator method

**The validity of a model is determined  
by the modeling objectives**

# References

- Henthorn, T., T. Krejcie, et al. (2008). "Early drug distribution: a generally neglected aspect of pharmacokinetics of particular relevance to intravenously administered anesthetic agents." Clin Pharmacol Ther **84**(1): 18-22.
- Henthorn, T. K., T. C. Krejcie, et al. (1992). "The relationship between alfentanil distribution kinetics and cardiac output." Clin Pharmacol Ther **52**(2): 190-196.
- Schalla, M. and M. Weiss (1999). "Pharmacokinetic curve fitting using numerical inverse Laplace transformation." European journal of pharmaceutical sciences **7**(4): 305-309.
- Weiss, M. (1986). "Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions. I. Log-convex drug disposition curves." Journal of pharmacokinetics and biopharmaceutics **14**(6): 635-657.
- Weiss, M. (1991). "Nonidentity of the steady-state volumes of distribution of the eliminating and noneliminating system." Journal of pharmaceutical sciences **80**(9): 908-910.
- Weiss, M. (1992). "The relevance of residence time theory to pharmacokinetics." European journal of clinical pharmacology **43**(6): 571-579.
- Weiss, M. (2007). "Residence time dispersion as a general measure of drug distribution kinetics: Estimation and physiological interpretation." Pharmaceutical research **24**(11): 2025-2030.
- Weiss, M. (2008). "How does obesity affect residence time dispersion and the shape of drug disposition curves? Thiopental as an example." Journal of pharmacokinetics and pharmacodynamics **35**(3): 325-336.
- Weiss, M., G. Hübner, et al. (1996). "Effects of cardiac output on disposition kinetics of sorbitol: recirculatory modelling." British journal of clinical pharmacology **41**(4): 261-268.
- Weiss, M. and K. S. Pang (1992). "Dynamics of drug distribution. I. Role of the second and third curve moments." Journal of pharmacokinetics and biopharmaceutics **20**(3): 253-278.
- Weiss, M., M. Reekers, et al. "Circulatory model of vascular and interstitial distribution kinetics of rocuronium: a population analysis in patients." Journal of pharmacokinetics and pharmacodynamics **38**(2): 165-178.
- Weiss, M. and M. S. Roberts (1996). "Tissue distribution kinetics as determinant of transit time dispersion of drugs in organs: application of a stochastic model to the rat hindlimb." Journal of pharmacokinetics and biopharmaceutics **24**(2): 173-196.